RNA Interference News and Research

RSS

Study on mitochondria function

For such crucial biological actors, much remains unknown about exactly how mitochondria function. A new study, published Aug. 12 in the online journal PLoS One, sheds light on mitochondrial biology. Using genetic engineering, researchers interrupted the activity of individual genes directly involved in the production of energy within mitochondria. "If we knock down the function of specific system components, what happens?" said study leader Marni J. Falk, M.D., who directs the Mitochondrial-Genetics Disease Clinic at The Children's Hospital of Philadelphia. "Our ultimate goal is to translate the knowledge into targeted therapies, that is, effective ways to intervene. But first we need to understand the underlying disease mechanisms."

25 Sep 2009

RXi Pharmaceuticals to present in vivo data of rxRNA compounds

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that it will be presenting new in vivo data on its self-delivering rxRNA compounds at a number of upcoming scientific conferences, detailed below.

16 Sep 2009

Scientists discover a new way for preventing liver metastases

Scientists in Switzerland have discovered a way to block the growth of human colon cancer cells, preventing the disease from reaching advanced stages and the development of liver metastases. The research, published today in EMBO Molecular Medicine, shows that blocking the so-called Hedgehog-GLI pathway can prevent the growth of tumours, metastatic lesions and cancer stem cells, the cells thought to lie at the root of cancer growth.

27 Aug 2009

Alnylam and Tekmira to collaborate on RNAi therapeutics

Alnylam Pharmaceuticals, Inc. and Tekmira Pharmaceuticals Corporation announced today that they will jointly participate in a new research collaboration focused on the discovery of novel cationic lipids and lipid nanoparticles for the systemic delivery of RNAi therapeutics.

6 Aug 2009

Identification of cholesterol regulating genes by targeted RNAi-screening

Scientists at the European Molecular Biology Laboratory (EMBL) and the University of Heidelberg, Germany, have come a step closer to understanding how cholesterol levels are regulated. In a study published today in the journal Cell Metabolism, the researchers identified 20 genes that are involved in this process. Besides giving scientists a better idea of where to look to uncover the mechanisms that ensure cholesterol balance is maintained, the discovery could lead to new treatments for cholesterol-related diseases.

7 Jul 2009

Specialized glycans act as tumor suppressors

Scientists at Burnham Institute for Medical Research (Burnham) have discovered that specialized complex sugar molecules (glycans) that anchor cells into place act as tumor suppressors in breast and prostate cancers.

6 Jul 2009

'Trojan horse' cancer therapy beats tumours resistant to chemotherapy

A new therapy to treat cancer has been developed by Australian scientists and it promises to have far fewer unpleasant side effects than conventional treatments and should also be much cheaper.

28 Jun 2009

Transplant drug Rapamycin stimulates immune memory

Rapamycin, a drug given to transplant recipients to suppress their immune systems, has a paradoxical effect on cells responsible for immune memory, scientists at the Emory Vaccine Center have discovered.

22 Jun 2009

Genome-wide map shows precisely where microRNAs do their work

MicroRNAs are the newest kid on the genetic block. By regulating the unzipping of genetic information, these tiny molecules have set the scientific world alight with such wide-ranging applications as onions that can't make you cry and therapeutic potential for new treatments for viral infections, cancer and degenerative diseases. But the question remains: How do they work?

17 Jun 2009

Intradigm issued RNA interference (RNAi) patent covering potent siRNA sequence

Intradigm Corporation has announced the issuance of United States patent 7,534,878, titled "Composition and Methods of RNAi Therapeutics for Treatment of Cancer and Other Neovascularization Diseases."

19 May 2009

New kind of treatment for sexually transmitted diseases

Yale researchers describe a breakthrough in safe and effective administration of potential antiviral drugs - small interfering RNA (siRNA) molecules that silence genes - the first step in development of a new kind of treatment for sexually transmitted diseases (STDs). The work is reported May 4 as an advance online publication of Nature Materials.

3 May 2009

Oral delivery system for RNAi therapeutics

Researchers at the University of Massachusetts Medical School (UMMS) report on a novel approach to the delivery of small bits of genetic material in order to silence genes using "RNA interference"-and in the process, discovered a potent method of suppressing inflammation in mice similar to what occurs in a range of human diseases.

30 Apr 2009

Welcome news on Dengue fever

The news that scientists in the United States have identified host factors which are critical to Dengue virus infection will be particularly welcome in tropical northern Queensland, which has suffered one of the worse Dengue fever outbreaks in decades.

26 Apr 2009

Scientists identify dozens of proteins the dengue fever virus depends upon

By painstakingly silencing genes one at a time, scientists at Duke University Medical Center have identified dozens of proteins the dengue fever virus depends upon to grow and spread among mosquitoes and humans.

22 Apr 2009

New Dengue virus discovery could lead to development of anti-dengue drugs

Doctors have no specific drugs to treat dengue fever, a viral illness spread by mosquitoes that sickens 50 million to 100 million people worldwide each year. Instead, the only treatments they can recommend for this painful and sometimes fatal illness (20,000 deaths globally each year) are fluids, rest and non-aspirin pain and fever reducers.

22 Apr 2009